Skip to main contentSkip to navigationSkip to search
ENZY  
SEK  %
Logotype

Prospectus & Memorandum

Disclaimer

You have selected a web site with information that is not intended to be published, published or distributed, directly or indirectly, in or to the United States, Australia, Japan, New Zealand, South Africa, Hong Kong, Singapore, South Korea, Switzerland, Canada or any other jurisdiction where such action may constitute violation of local securities laws or regulations.

You have selected a web site with information that is not intended to be published, published or distributed, directly or indirectly, in or to the United States, Australia, Japan, New Zealand, South Africa, Hong Kong, Singapore, South Korea, Switzerland, Canada or any other jurisdiction where such action may constitute violation of local securities laws or regulations.

Disclaimer

You have selected a web site with information that is not intended to be published or distributed, directly or indirectly, in or to the United States, Russia, Belarus, Australia, Hong Kong, Japan, Canada, New Zealand, South Korea, Switzerland, Singapore, South Africa or any other jurisdiction where such action may constitute violation of local securities laws or regulations. By clicking "Yes, I accept" below you are agreeing to the terms of access to this website. 

The offer to subscribe for shares in Enzymatica AB (publ) in accordance with the terms of the prospectus is not aimed at persons whose participation in the offer requires additional prospectus, registration measures or other measures than those that follow from Swedish law. The prospectus and other documents relating to the offer may not be distributed in any country where such distribution or the offer requires additional measures than those specified in the previous sentence or contravene rules in such country. Neither subscription rights, paid subscription shares (BTAs) nor newly issued shares have been registered or will be registered in accordance with the United States Securities Act of 1933 in force, or under applicable law in Russia, Belarus, Australia, Hong Kong, Japan, Canada, New Zealand, South Korea, Switzerland, Singapore or South Africa and thus may not be offered or transferred, directly or indirectly, to a resident of any of these countries. The notification of subscription of shares in contravention of the above may be considered invalid and be disregarded. 

Disputes arising from the offer, the contents of the prospectus and related legal matters shall be decided exclusively by the Swedish court. Swedish law applies exclusively to the prospectus and to the offer according to the prospectus. 

In order to be entitled to access the information on the following web site, you must, if you access the following web site, have confirmed and stated that (i) you have read and accept the terms and conditions stated above and (ii) you are not in the United States, Russia, Belarus, Australia, Hong Kong, Japan, Canada, New Zealand, South Korea, Switzerland, Singapore or South Africa.

By clicking "Yes, I accept" below you are agreeing to the terms of access to this website.

You have selected a web site with information that is not intended to be published, published or distributed, directly or indirectly, in or to the United States, Australia, Japan, New Zealand, South Africa, Hong Kong, Singapore, South Korea, Switzerland, Canada or any other jurisdiction where such action may constitute violation of local securities laws or regulations.

Prospectus & Memorandum

Rights Issue February 2024

February 19, 2024

Documents

Memorandum Enzymatica 2024-02-19 (in Swedish)